These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 12856385)

  • 41. A randomized, double-blind, placebo-controlled trial of the efficacy and tolerability of a 4-mg dose of subcutaneous sumatriptan for the treatment of acute migraine attacks in adults.
    Wendt J; Cady R; Singer R; Peters K; Webster C; Kori S; Byrd S
    Clin Ther; 2006 Apr; 28(4):517-26. PubMed ID: 16750463
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy and tolerability of sumatriptan injection for the treatment of morning migraine: two multicenter, prospective, randomized, double-blind, controlled studies in adults.
    Winner P; Adelman J; Aurora S; Lener ME; Ames M
    Clin Ther; 2006 Oct; 28(10):1582-91. PubMed ID: 17157114
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Zolmitriptan nasal spray exhibits good long-term safety and tolerability in migraine: results of the INDEX trial.
    Dowson AJ; Charlesworth BR; Green J; Färkkilä M; Diener HC; Hansen SB; Gawel M;
    Headache; 2005 Jan; 45(1):17-24. PubMed ID: 15663608
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Lack of pharmacokinetic interaction between butorphanol tartrate nasal spray and sumatriptan succinate.
    Srinivas NR; Shyu WC; Upmalis D; Lee JS; Barbhaiya RH
    J Clin Pharmacol; 1995 Apr; 35(4):432-7. PubMed ID: 7650235
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical implications for breath-powered powder sumatriptan intranasal treatment.
    Tepper SJ
    Headache; 2013 Sep; 53(8):1341-9. PubMed ID: 23809006
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparative pharmacokinetics between a microdose and therapeutic dose for clarithromycin, sumatriptan, propafenone, paracetamol (acetaminophen), and phenobarbital in human volunteers.
    Lappin G; Shishikura Y; Jochemsen R; Weaver RJ; Gesson C; Brian Houston J; Oosterhuis B; Bjerrum OJ; Grynkiewicz G; Alder J; Rowland M; Garner C
    Eur J Pharm Sci; 2011 Jun; 43(3):141-50. PubMed ID: 21540108
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacokinetics, Safety, and Tolerability Following the Administration of a Single Dose of a Combination Tablet Containing Sumatriptan and Naproxen Sodium in Adolescent Patients With Migraine and in Healthy Adult Volunteers.
    Berges A; Robertson J; Upward J; Meyers S; Chen C
    Clin Pharmacol Drug Dev; 2012 Jul; 1(3):85-92. PubMed ID: 27121335
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Intranasal sumatriptan: in adolescents with migraine.
    Curran MP; Evans HC; Wagstaff AJ
    CNS Drugs; 2005; 19(4):335-43; discussion 345-6. PubMed ID: 15813647
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacokinetic Characterization and Dose Selection of a Novel Sumatriptan Nasal Spray Formulation, DFN-02.
    Pal A; Gautam A; Munjal S
    J Clin Pharmacol; 2017 Nov; 57(11):1472-1478. PubMed ID: 28597922
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mixed effect modeling of sumatriptan pharmacokinetics during drug development: II. From healthy subjects to phase 2 dose ranging in patients.
    Cosson VF; Fuseau E
    J Pharmacokinet Biopharm; 1999 Apr; 27(2):149-71. PubMed ID: 10567953
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A review of clinical safety data for sumatriptan nasal powder administered by a breath powered exhalation delivery system in the acute treatment of migraine.
    Silberstein SD
    Expert Opin Drug Saf; 2018 Jan; 17(1):89-97. PubMed ID: 28994319
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Interindividual variability of oral sumatriptan pharmacokinetics and of clinical response in migraine patients.
    Ferrari A; Pinetti D; Bertolini A; Coccia C; Sternieri E
    Eur J Clin Pharmacol; 2008 May; 64(5):489-95. PubMed ID: 18180912
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparative clinical pharmacokinetics of single doses of sumatriptan following subcutaneous, oral, rectal and intranasal administration.
    Duquesnoy C; Mamet JP; Sumner D; Fuseau E
    Eur J Pharm Sci; 1998 Apr; 6(2):99-104. PubMed ID: 9795022
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The pharmacokinetics of sumatriptan when administered with clarithromycin in healthy volunteers.
    Moore KH; Leese PT; McNeal S; Gray P; O'Quinn S; Bye C; Sale M
    Clin Ther; 2002 Apr; 24(4):583-94. PubMed ID: 12017403
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacokinetics of naratriptan in adolescent subjects with a history of migraine.
    Christensen ML; Eades SK; Fuseau E; Kempsford RD; Phelps SJ; Hak LJ
    J Clin Pharmacol; 2001 Feb; 41(2):170-5. PubMed ID: 11210397
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Effect of sumatriptan on facial temperature variations, blood pressure and electrocardiogram in healthy subjects and patients with migraine without aura].
    Paterna S; Parrinello G; Pinto A; Arrostuto A; Cottone C; Di Silvestre G; Maniscalchi T; Licata G
    Clin Ter; 1995; 146(6-7):469-76. PubMed ID: 7586999
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Sumatriptan clinical pharmacokinetics.
    Scott AK
    Clin Pharmacokinet; 1994 Nov; 27(5):337-44. PubMed ID: 7851052
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pronounced effect of caprylocaproyl macrogolglycerides on nasal absorption of IS-159, a peptide serotonin 1B/1D-receptor agonist.
    Dingemanse J; Soubrouillard C; Paris J; Pisano P; Blin O
    Clin Pharmacol Ther; 2000 Aug; 68(2):114-21. PubMed ID: 10976542
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A pharmacokinetic interaction study between butorphanol and sumatriptan nasal sprays in healthy subjects: importance of the timing of butorphanol administration.
    Vachharajani NN; Shyu WC; Nichola PS; Boulton DW
    Cephalalgia; 2002 May; 22(4):282-7. PubMed ID: 12100090
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Chronopharmacokinetics of sumatriptan in healthy human subjects.
    Poondru S; Devaraj R; Boinpally RR; Yamasani MR
    J Pharm Pharmacol; 2000 Sep; 52(9):1085-90. PubMed ID: 11045888
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.